The American College of Emergency Physicians (ACEP) believes that scientifically valid and well-controlled clinical trials conducted under federal investigational new drug applications are necessary to assess the safety and effectiveness of all new drugs, including cannabis and cannabis derivative products, for medical use. Currently, in many states, cannabis and related cannabinoids are being recommended for patient use by physicians when little evidence has been provided regarding appropriate indications, efficacy, dosages, and precautions of these drugs. ACEP supports the rescheduling of cannabis and encourages the Food & Drug Administration (FDA), Drug Enforcement Administration (DEA), and other appropriate organizations to facilitate scientifically valid, well-controlled studies of the use of cannabis and cannabis derivative products for treatment of disease and of its impact on societal health.